Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens-Reference-Cited by-同舟云学术

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens

Published:2013-07-24 Issue:9 Volume:88 Page:765-770
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Bagratuni Tina¹,Kastritis Efstathios¹,Politou Marianna²,Roussou Maria¹,Kostouros Efthimios¹,Gavriatopoulou Maria¹,Eleutherakis-Papaiakovou Evangelos¹,Kanelias Nikolaos¹,Terpos Evangelos¹,Dimopoulos Meletios A.¹

Affiliation:

1. Department of Clinical Therapeutics; University of Athens; School of Medicine; Athens; Greece

2. Aretaieion Hospital; University of Athens, School of Medicine; Athens; Greece

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.23504/fullpdf

Reference38 articles.

1. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies;Vallet;Expert Opin Pharmacother,2012

2. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma;Dimopoulos;N Engl J Med,2007

3. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America;Weber;N Engl J Med,2007

4. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial;Rajkumar;Lancet Oncol,2010

5. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma;Schey;J Clin Oncol,2004

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis;Thrombosis and Haemostasis;2024-05-20

2. Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma;Thrombosis Journal;2023-10-04

3. Thrombosis in multiple myeloma: mechanisms, risk assessment and management;Leukemia & Lymphoma;2023-08-16

4. Platelet Parameters as Biomarkers for Thrombosis Risk in Cancer: A Systematic Review and Meta-analysis;Seminars in Thrombosis and Hemostasis;2023-03-15

5. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma;Cancers;2022-12-16